Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis

NCT: NCT04287647 · TERMINATED

NCT IDNCT04287647
StatusTERMINATED
Start Date2019-05-15
Completion2026-05-27
SponsorNorthwestern University (OTHER)
First posted
Last updated

Brief Summary

This is a prospective sham study to investigate the role of transpyloric stenting with lumen apposing metal stent (LAMS) as a predictor for clinical response to gastric per-oral endoscopic pyloromyotomy (GPOEM) for refractory gastroparesis. The study hypothesizes that clinical improvement with transpyloric stenting in patients with refractory gastroparesis is a predictor of subsequent clinical success of GPOEM.

Frequently Asked Questions

What is Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis?

Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis is a clinical trial registered under NCT04287647. Current status: TERMINATED.

What is the status of NCT04287647?

The current status of NCT04287647 (Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis) is: TERMINATED.

When did Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis start?

Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis started on 2019-05-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.